Document is current
Any future updates will be listed below
-
Authors
Pokrzywinski, Robin https://orcid.org/0000-0002-1781-8197
Bartke, Danaé
Clucas, Claudine
Machuzak, Kathy
Pinto, Lionel
-
Funding
Funding for this research was provided by:
Travere Therapeutics, Inc. (Travere Therapeutics, Inc.)
- License Information
-
More Information
Article History
Received: 10 June 2024
Accepted: 23 January 2025
First Online: 6 March 2025
Change Date: 16 April 2025
Change Type: Update
Change Details: This article has been updated to amend figure 1
Declarations
:
: All research procedures were performed in accordance with the Declaration of Helsinki. The study protocol (Pro00064873) was approved by Advarra (Columbia, MD, USA), a central institutional review board. All participants provided written consent or assent before participating.
: No identifiable information is provided; as such, this is not applicable.
: RP and CC are employees of Evidera, part of the PPD clinical research business within Thermo Fisher Scientific, which received funding from Travere Therapeutics, Inc. DB is employed by HCU Network America, which has received research grant support and/or speaker/consultancy fees from Travere Therapeutics, Inc. LP and KM are former employees of and own stock in Travere Therapeutics, Inc.
